|
Jul 16, 2012, 03.46 PM IST
Citigroup raises its target price of drug maker Lupin to Rs 640 from Rs 570, while maintaining its "buy" rating, after meeting with management. Lupin shares last up 3.1% at Rs 572.05.
"Our meeting with Lupin reinforces our confidence on the company's ability to sustain its excellent track record on growth & capital efficiency," Citigroup says in a note dated Monday. Citi expects "healthy" growth and "improved profitability" in each of its key markets: India, the United States, and Japan. However, Citi lowers its fiscal 2013-14 EPS forecast for Lupin by around 5% due to higher effective tax rate assumptions.
Related News Set email alert for |
Action in Lupin
 From DJ EU Officials Spain Aid Cap Of 100 Bn Euros 'should Be Enough'  The latest earning numbers FIRST on CNBC-TV18
News Videos
|
